Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey
Open Forum Infectious Diseases · 29.08.2025 · 12 (9)
DOI: 10.1093/ofid/ofaf580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 15.09.2025. Verfasst von Jack W McHugh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Department of Medicine, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
Recent clinical trial evidence supports broader use of partial oral therapy (POT) for infective endocarditis (IE), yet real-world uptake in the U.S. has not been investigated.
Methods
Adult infectious diseases (ID) physician members of the Infectious Diseases Society of America Emerging Infections Network were surveyed in April–May 2025. A 10-item instrument captured frequency of POT, organism-specific influence, decision factors, barriers, and facilitators.
Results
Among 1531 members, 516 (34%) responded; 452 (88%) of them managed IE. POT was uncommon: 16% never used, 53% used in ≤10% of cases, and only 10% used in >25% of patients. Frequent POT rose with caseload (23% in physicians treating >50 IE cases year vs ≤9% in lower-volume groups, P < .001) and with fewer years in clinical practice (13% in <5 yrs vs 5% in ≥25 yrs, P = .013). Comfort with POT depended on the pathogen: 66% were comfortable switching for Streptococcus spp., 52% for Gram-negative bacilli, 19% for methicillin-resistant Staphylococcus aureus. Three quarters of those who used POT finished with a single agent. In people who inject drugs, 34% of physicians often or always considered an oral regimen. Availability of an active oral agent (75%) and the pathogen involved (69%) were the leading decision drivers; principal barriers were fear of relapse (72%), adherence concerns (53%), and insufficient evidence (48%). Respondents most desired clearer guidelines (75%) and additional data (71%).
Conclusions
U.S. adult ID physicians adopt POT for IE sparingly. Updated IE treatment guidelines, additional clinical trial data, and broader access to complex outpatient antimicrobial therapy services may facilitate wider adoption.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Public Health, Department of Medicine, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Infectious Diseases, Carver College of Medicine University of Iowa, Iowa City, Iowa, USA.
ORCID-Profile: Jack W McHugh, Larry M Baddour, Supavit Chesdachai, Philip M Polgreen, Daniel C DeSimone
Förderung
- Centers for Disease Control and Prevention
Zitieren
APA
McHugh, J. W., Baddour, L. M., Chesdachai, S., Beekmann, S. E., Polgreen, P. M., Wilson, W. R., & DeSimone, D. C. (2025). Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey. Open Forum Infectious Diseases, 12(9). https://doi.org/10.1093/ofid/ofaf580
Vancouver
McHugh JW, Baddour LM, Chesdachai S, Beekmann SE, Polgreen PM, Wilson WR, et al. Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey. Open Forum Infectious Diseases. 2025;12(9). doi:10.1093/ofid/ofaf580
BibTeX
@article{McHugh2025,
author = {McHugh, Jack W and Baddour, Larry M and Chesdachai, Supavit and Beekmann, Susan E and Polgreen, Philip M and Wilson, Walter R and DeSimone, Daniel C},
title = {Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {9},
doi = {10.1093/ofid/ofaf580}
}
EUVIMED